Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Patch · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Transdermal/Patch (Bupivacaine TTS [Eladur™]) | DRUG | - |
Inclusion Criteria: * Male or females age 21 years or older. * Pain in thoracic or lumbar regions for a minimum of 90 days after crusting of Herpes Zoster (HZ) lesions. * Stable prescribed medications regimen (including opioids, anticonvulsants, and tricyclic antidepressants). * Intact, unbroken sk...
Patch is an investigational drug being studied for the treatment of postherpetic neuralgia, a type of nerve pain that occurs after a shingles infection. It is currently in Phase 2 clinical development and has not been approved by the FDA.
Patch is being developed by DURECT Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol DRRX. The company is conducting clinical trials to evaluate the safety and efficacy of Patch for postherpetic neuralgia.
Patch is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its effects in patients with postherpetic neuralgia.
Patch has been studied in a Phase 2 clinical trial with the identifier NCT00478179. This trial, titled 'Study of a Bupivacaine Patch (Eladur™) to Treat Post-Herpetic Neuralgia,' was completed in the United States and enrolled 60 participants aged 21 years and older.
Yes, Patch is also known as Eladur. The clinical trial NCT00478179 refers to the drug as a Bupivacaine Patch (Eladur™). This alternative name may be used in research and clinical contexts.